Using camrelizumab with chemotherapy for advanced lung cancer treatment
Efficacy，Safety and Cost-effectiveness Evaluation of Camrelizumab Plus Chemotherapy in First-line Treatment of Patients With Non-squamous Non-small-cell Lung Cancer
This study is testing if adding camrelizumab to chemotherapy helps people with advanced lung cancer feel better compared to just standard chemotherapy or chemotherapy with another type of treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Affiliated Hospital of Nantong University Academic / other |
| Drugs / interventions | chemotherapy, camrelizumab |
| Locations | 1 site (Nantong, Jiangsu) |
| Trial ID | NCT05387512 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness and safety of camrelizumab combined with chemotherapy in patients with advanced non-squamous non-small cell lung cancer who are EGFR and ALK negative. It compares this combination treatment to standard chemotherapy alone or chemotherapy with antiangiogenic therapy. The study employs a Markov Model to analyze the cost-effectiveness of the treatments, utilizing real-world data. Additionally, it includes sensitivity analyses to assess the robustness of the findings.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with a histopathological diagnosis of advanced non-squamous non-small cell lung cancer who are EGFR and ALK negative and have not received prior systemic chemotherapy.
Not a fit: Patients with lung squamous cell carcinoma or those with serious comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for patients with advanced non-squamous non-small cell lung cancer.
How similar studies have performed: While this approach is being evaluated in a real-world setting, similar studies have shown promise in assessing the effectiveness of combination therapies in lung cancer treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1) Histopathological diagnosis of non-squamous non-small cell lung cancer; 2) EGFR gene mutation negative and ALK negative, and did not receive systematic chemotherapy; 3) Older than 18 years of age; 4) Pathological stage IIIB or IV; 5) ECOG (Eastern Oncology Collaboration group) score 0-1; 4) Ecg and liver and kidney function are normal; 6) No second primary tumor disease or serious complications. Exclusion Criteria: * 1) Patients with lung squamous cell carcinoma diagnosed by histopathology; (2) Patients with serious cardiovascular disease, active gastrointestinal bleeding, obvious coagulopathy, complicated with other malignant tumors, and drug allergy were excluded; 3) Patients with poor treatment compliance and incomplete case data.
Where this trial is running
Nantong, Jiangsu
- Department of Pharmacy, Affiliated Hospital of Nantong University — Nantong, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Zhiyuan Tang, Doctor
- Email: tina2951@sina.com
- Phone: 18862804577
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.